The European Medicines Agency committee said the benefits of the new drug, Kisunla, did not outweigh the risks, and it ...

Zunveyl (benzgalantamine) is now available for the treatment of mild to moderate dementia of the Alzheimer type in adults.

For individuals with dominantly inherited Alzheimer disease, long-term treatment with gantenerumab may delay clinical decline ...

The company behind the drug donanemab said it will ask regulators to reconsider the decision. View on euronews ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The EU’s medicines regulator has declined to approve Eli Lilly’s new Alzheimer’s drug, deciding the risks of serious and potentially fatal side effects outweigh the benefits of slowing progression of ...

Eli Lilly, which is seeking European approval of Kisunla for the treatment of early symptomatic Alzheimer's, said it will seek re-examination by CHMP. The Indianapolis drugmaker said it remains ...

Eli Lilly (LLY) stock in focus as an expert panel of the EU drug regulator declines to endorse its Alzheimer's drug Kisunla.

The European Union's drugs regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's small impact on ...

INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness ...

As we wait for a breakthrough that can block or reverse Alzheimer’s disease, there is some consolation that we finally have three kinds of medications and a treatment that can ...